ESTRO 2024 - Abstract Book

S365

Beachytherapy - Physics

ESTRO 2024

Bladder/Prostate

15

17.5

0.56

91.82

12 17 14 13 12 17 16 15 17

20.7 10.4 21.6 16.3 15.9 26.4 42.7 25.9 66.8 15.6 18.5 21.4 17.2 11.1 12.4 10.2 22.4 43.2 8.51 23.0 15.3 25 4.3 32

0.61 0.57 0.67 0.68 0.54 0.72 0.72 0.66 0.54 0.49 0.30 0.30 0.33 0.75 0.50 0.67 0.72 0.79 0.77 0.74 0.68 0.62 0.59 0.63 0.62 0.45 0.61 0.61 0.50 NR

90.61 95.14 94.18 82.82 87.38 96.78 96.81 99.47 87.94 93.93 95.76 91.10 85.40 94.31 93.04 96.00 91.42 91.22 95.78 99.65 94.21 96.49 99.18 85.57 99.23 91.71 98.42 89.34 87.78 94.25

Table

1: Sites treated

with the CTV volume received

Cervix

9 2 2 3 8 7

Perineum

Prostate

14 11 11 11 16 18 12 18 13

Urethra/Bladder

18

21.4

6 6 1

9.5

Vagina

19.8 22.5 30.7 10.4

Vagina/Urethra

11 11

Vulva

prescription dose and the coverage Index (COIN). The CTV V 90% were not recorded as they were treated using Nucletron Plato System which was decommissioned in 2009.

Conclusion:

The generated treatment plans exhibited robustness, and 84% of the plans have resulted in COIN values 3 of higher than 0.5. The CTV coverage was good, with a minimum V 100% of 82.3% and the average V 100% of 93%.

Keywords: displacement, robustness, coverage

References:

1 Gaze MN, Smeulders N, Ackwerh R, Allen C, Bal N, Boutros M, Cho A, Eminowicz G, Gill E, Fittall MW, Humphries PD, Lim P, Mushtaq I, Nguyen T, Peet C, Pendse D, Polhill S, Rees H, Sands G, Shankar A, Slater O, Sullivan T, Hoskin PJ. A National Referral Service for Paediatric Brachytherapy: An Evolving Practice and Outcomes